Zeki Kocaata
Senior Director, Global Real World Evidence & Health Outcomes Lead Vaccines GlaxoSmithKline
Zeki Kocaata is a global pharmaceutical leader with 10+ years of experience delivering Real-World Evidence and Phase 4 strategies that directly enable market access, pricing optimization, and long-term product success. At GSK, he leads global RWE and health outcomes strategy across vaccines, designing and executing impactful evidence programs from development through launch and lifecycle expansion. He has authored 40+ publications and led 20+ studies that strengthened reimbursement cases, supported policy recommendations, and expanded commercial reach into new markets and patient groups. With a strong foundation in epidemiology, health economics, and causal inference, Zeki is known for translating scientifically rigorous evidence into strategic value for patients, payers, and portfolios alike.
Seminars
- How can pharma, registries, and vendors collaborate to avoid duplication and improve efficiency in finding usable datasets?
- What frameworks are needed to establish fair and transparent remuneration for physicians, patients, and database owners?
- How do we balance sustainability of smaller registries with industry’s need for scale and interoperability?
- How should pharma assess the risks of supporting new registries, and what funding and contracting models best incentivise long-term patient recruitment?
- Where can AI and automation play a role in reducing healthcare system burden and improving data timeliness?
- Use RWE to inform study design, feasibility, and decision-making to prevent costly delays and reduce early clinical delays
- Close evidence gaps before launch to secure smoother pricing and reimbursement pathways strengthening HTA readiness
- Deploy targeted RWE to demonstrate real-world value and support confident market entry.
